Beam Therapeutics
BEAM
Market cap $2.13B

21.16 USD

-0.87

3.95%

At close Jul 11, 4:00 PM EDT

After hours

21.30

+0.14

0.66%

1 day

-3.95%

5 days

6.60%

1 month

18.28%

3 months

36.78%

6 months

-17.15%

Year to date

-14.33%

1 year

-18.24%

5 years

-15.46%

10 years

12.85%

About: Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Employees: 502

Healthcare Biotechnology

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

113% more repeat investments, than reductions

Existing positions increased: 100 | Existing positions reduced: 47

100% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 4 (+2) [Q1 2025]

52% more call options, than puts

Call options by funds: $11.8M | Put options by funds: $7.81M

31% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 32

3.14% more ownership

Funds ownership: 98.36% [Q4 2024] → 101.5% (+3.14%) [Q1 2025]

3% more funds holding

Funds holding: 230 [Q4 2024] → 236 (+6) [Q1 2025]

2% less capital invested

Capital invested by funds: $2.02B [Q4 2024] → $1.99B (-$35.6M) [Q1 2025]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$25

18%

upside

Avg. target

$50

136%

upside

High target

$70

231%

upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

Guggenheim Debjit Chattopadhyay	160%upside $55	Buy Maintained	7 May 2025
Wells Fargo Yanan Zhu	231%upside $70	Overweight Maintained	7 May 2025
Barclays Gena Wang	18%upside $25	Equal-Weight Maintained	7 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about BEAM published over the past 30 days

Zacks Investment Research

Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains?

Beam Therapeutics (BEAM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains?

The Motley Fool

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

Zacks Investment Research

3 Promising Genomics Stocks to Keep an Eye On in 2025

Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.

3 Promising Genomics Stocks to Keep an Eye On in 2025

Schaeffers Research

Top Stock Pick Report: V-Shaped Rallies Everywhere

Back in late March, we power ranked our Top Stock Picks of 2025. There was some success and lessons to be drawn, but if we're being honest, this wasn't the entire story. There was red ink everywhere and combined with the looming threat of unilateral tariffs on ‘Liberation Day,' fear had grown surrounding a potential recession hitting by the time a second-quarter check-in came around.

Top Stock Pick Report: V-Shaped Rallies Everywhere

Investors Business Daily

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases

Positive results released from updated data with 17 SCD patients with VOC from the phase 1/2 BEACON study. No VOC after engraftment and >60% HbF induction. Additional results of 30 SCD patients from phase 1/2 BEACON study using BEAM-101, expected in the 2nd half of 2025. The global sickle cell disease market is expected to reach $12.38 billion by 2032.

Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to

Zacks Investment Research

Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?

Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?

Zacks Investment Research

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

Beam Therapeutics rises after the FDA grants orphan drug status to its gene-editing therapy BEAM-101 for sickle cell disease.

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD).

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

See News Rankings

Charts implemented using Lightweight Charts™